Results 91 to 100 of about 66,892 (264)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Screening for Natural Inhibitors of Topoisomerases I from Rhamnus davurica by Affinity Ultrafiltration and High-Performance Liquid Chromatography–Mass Spectrometry

Frontiers in Plant Science, 2017
Topoisomerase I (Topo I) catalyzes topological interconversion of duplex DNA during DNA replication and transcription, and has been deemed as important antineoplastic targets.
Guilin Chen, Guilin Chen, Mingquan Guo, Mingquan Guo   +3 more
doaj   +1 more source

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo [PDF]

, 2016
Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment of ...
Berek, Jonathan S, Chung, Young Min, Hu, Mickey C-T, Ma, Jessica, Park, See-Hyoung, Yang, Qin   +5 more
core   +2 more sources

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

In vitro anticancer studies of a small library of cyclic lipopeptides against the human cervix adenocarcinoma HeLa cells [PDF]

Journal of the Serbian Chemical Society
Various cyclic lipopeptides (CLPs, 23 compounds) were tested for their antitumor potential against human cervix adenocarcinoma HeLa cells. From the fast screening (tested concentrations: 0.01 and 10 μM) compound 10 ((12S,6S,10S,13S)-6-((R)-sec-butyl)-7 ...
Hmedat Ali N., Morejón Micjel C., Rivera Daniel G., Pantelić Nebojša Đ., Wessjohann Ludger A., Kaluđerović Goran N.   +5 more
doaj   +1 more source

Impacts of in vivo and in vitro exposures to tamoxifen: comparative effects on human cells and marine organisms [PDF]

, 2019
Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive (HER+) breast cancer in both pre- and post-menopausal patients and may undergo metabolic activation in organisms that share similar receptors and thus face comparable ...
Abessa, D. M. S., Bebianno, M., Carriço, T., Fernandes, E., Fonseca, T. G., Tavares, A.   +5 more
core   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Ruthenium polypyridyl complexes and their modes of interaction with DNA : is there a correlation between these interactions and the antitumor activity of the compounds? [PDF]

, 2008
Various interaction modes between a group of six ruthenium polypyridyl complexes and DNA have been studied using a number of spectroscopic techniques.
A Boccarelli, A Habtemariam, A Kirpal, A Oleksi, A Rodger, A Rodger, ACG Hotze, AEM Boelrijk, AH Velders, Alison Rodger, Anna C. G. Hotze, Anna Leczkowska, B Armitage, B Elias, B Nordén, B Nordén, C Hiort, C Uerpmann, CG Hartinger, CS Allardyce, DZM Coggan, E Corral, E Corral, EI Montero, EI Montero, ER Jamieson, Eva Corral, G Natile, G Sava, GI Pascu, H Chao, H Tada, Hans den Dulk, HM Chen, I Kostova, I Meistermann, J Kasparkova, J Kasparkova, J Reedijk, J Reedijk, J Reedijk, J Reedijk, Jan Reedijk, JP Macquet, K Davia, K Karidi, K Lang, M Beusichem van, M Coluccia, M Howegrant, MC Alley, ME Reichmann, Michael J. Hannon, MJ Clarke, MJ Hannon, MJ Hannon, MR Boyd, N Farrell, N Farrell, N Grover, O Nováková, O Nováková, PA Adcock, PJ Loehrer, PM Vliet van, RA Vilaplana, RA Vilaplana, SM Kelly, SR Grguric-Sipka, SR Smith, T Mosmann, U Bierbach, V Brabec, V Brabec, Y Zou, YP Keepers   +75 more
core   +3 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source